Abstract CT020: Long-term outcomes of patients with TRK fusion cancer treated with larotrectinib
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2021-ct020
Abstract: Introduction: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. Larotrectinib is a first-in-class, highly selective, central nervous system (CNS)-active TRK inhibitor approved in over 40 countries, including the US,… read more here.
Keywords: response; trk fusion; cancer; patients trk ... See more keywords